Adaptive Biotechnologies Corporation
ADPT
Hisse Senetlerindeki Sıralama
#4135
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Hisse Fiyatı
$24.59
Son senkronizasyon: 2026-10-20
Piyasa Değeri
$3.92B
Değişim (1 gün)
2.65%
Değişim (1 yıl)
41.70%
Ülke
US
Ticaret Adaptive Biotechnologies Corporation (ADPT)
Kategori
Healthcare
Adaptive Biotechnologies Corporation (ADPT) için gelir
Jun 2026 itibarıyla gelir TTM: $308.08M
Adaptive Biotechnologies Corporation şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $308.08M'dir. 2024 yılında şirketin geliri $178.96M önceki yıla göre artış 2023 yılındaki $170.28M gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Adaptive Biotechnologies Corporation için 2017 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $308.08M | 11.23% |
| 2025 | $276.98M | 54.77% |
| 2024 | $178.96M | 5.10% |
| 2023 | $170.28M | -8.11% |
| 2022 | $185.31M | 20.06% |
| 2021 | $154.34M | 56.88% |
| 2020 | $98.38M | 15.65% |
| 2019 | $85.07M | 52.83% |
| 2018 | $55.66M | 44.77% |
| 2017 | $38.45M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| $12.62B | 3,997.72% |
US
|
|
| $2.23B | 623.19% |
US
|
|
| $15.74B | 5,010.45% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,854.45% |
NL
|
